International Journal of Preventive Medicine (Int J Prev Med)2008-780210102020020921712171ENDepartment of Internal Medicine, Semnan University of Medical Sciences, SemnanDepartment of Internal Medicine, Semnan University of Medical Sciences, SemnanDepartment of Internal Medicine, Semnan University of Medical Sciences, SemnanDepartment of Pathology, Isfahan University of Medical Sciences, IsfahanSocial Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan20200126<p><span class="fontstyle0"><strong>Introduction</strong>: </span><span class="fontstyle2">Cisplatin is a widely used anti‑cancer drug that is commonly administered for the<br />treatment of various cancers. However, nephrotoxicity is the most important side effect of this<br />drug which limits its use. This study aimed to investigate the protective effect of Cystone against<br />nephrotoxicity induced by Cisplatin in patients with cancer. </span></p><p><span class="fontstyle0"><strong>Methods</strong>: </span><span class="fontstyle2">This pilot clinical trial study<br />was conducted on 43 cancer patients treated with Cisplatin (75 mg/m</span><span class="fontstyle2" style="font-size: 5pt;">2 </span><span class="fontstyle2">for a period of six months).<br />The subjects were divided into treatment group (receiving Cystone, two per 8 hours; </span><span class="fontstyle3">n </span><span class="fontstyle2">= 21) and<br />control group (</span><span class="fontstyle3">n </span><span class="fontstyle2">= 22). The two groups were compared with each other in terms of demographic and<br />laboratory variables. </span></p><p><span class="fontstyle0"><strong>Results</strong>: </span><span class="fontstyle2">In the intervention group receiving Cystone, serum creatinine‑based<br />GFR level (</span><span class="fontstyle3">P </span><span class="fontstyle2">= 0.453) and 24‑hour urine creatinine‑based GFR level (</span><span class="fontstyle3">P </span><span class="fontstyle2">= 0.397) did not change<br />significantly during the studied period, but in the control group, serum creatinine‑based GFR<br />level (</span><span class="fontstyle3">P </span><span class="fontstyle2">= 0.013) and 24‑hour urine creatinine‑based GFR level (</span><span class="fontstyle3">P </span><span class="fontstyle2">= 0.016) significantly changed.<br />Serum creatinine‑based GFR level increased by 2.3 units in the intervention group and 10.5 units in<br />the control group (</span><span class="fontstyle3">P </span><span class="fontstyle2">= 0.005) in the six months of the study. At the end of the sixth month, 24‑hour<br />urine creatinine‑based GFR level increased by 2.2 units in the intervention group and 0.8 unit in the<br />control group (</span><span class="fontstyle3">P </span><span class="fontstyle2">= 0.008). </span></p><p><span class="fontstyle0"><strong>Conclusions</strong>: </span><span class="fontstyle2">The use of Cystone resulted in more stable kidney function<br />indices in the intervention group, as compared with the control group. Therefore, Cystone seems to<br />have a protective effect against nephrotoxicity induced by Cisplatin in cancer patients.<br /></span></p><p><span class="fontstyle0" style="color: #00652e;"><strong>Keywords</strong>: </span><span class="fontstyle3">Cisplatin, cystone, neoplasm, nephrotoxicity</span></p>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/2171http://ijpm.mui.ac.ir/index.php/ijpm/article/download/2171/717717967